Aditxt Inc. (ADTX)vsModerna Inc (MRNA)
ADTX
Aditxt Inc.
$0.01
+5.45%
HEALTHCARE · Cap: $9.48M
MRNA
Moderna Inc
$142.77
-4.60%
HEALTHCARE · Cap: $57.00B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 15536860% more annual revenue ($2.23B vs $14,340). ADTX leads profitability with a 0.0% profit margin vs -141.4%. ADTX earns a higher WallStSmart Score of 33/100 (F).
ADTX
Avoid33
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADTX.
Margin of Safety
+70.0%
Fair Value
$135.25
Current Price
$142.77
$7.52 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1094.0% year-over-year
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 8.4x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ADTX
The strongest argument for ADTX centers on Revenue Growth, Debt/Equity. Revenue growth of 1094.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ADTX
The primary concerns for ADTX are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ADTX profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 0.90 — expect wider price swings.
ADTX is growing revenue faster at 1094.0% — sustainability is the question.
ADTX generates stronger free cash flow (-5M), providing more financial flexibility.
Bottom Line
ADTX scores higher overall (33/100 vs 21/100) and 1094.0% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aditxt Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Aditxt Inc. is an innovative biotechnology company dedicated to transforming healthcare through its proprietary immune modulation and personalized medicine platform. Focused on enhancing immune responses to address chronic diseases and allergies, Aditxt aims to significantly improve patient outcomes. With a robust pipeline of therapeutic candidates supported by comprehensive research and strategic collaborations, the company is poised to be a leader in the rapidly evolving field of immune-based therapies. Aditxt's commitment to scientific advancement and patient-centric solutions positions it at the forefront of immunology and the broader healthcare landscape.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?